Cequa (cyclosporine ophthalmic solution; Sun Pharma) 0.09% is now available for use in patients with keratoconjunctivitis sicca or dry eye disease.

Cequa contains the highest concentration of cyclosporine, a calcineurin inhibitor immunosuppressant, for ophthalmic use that is approved by the Food and Drug Administration (FDA), and is the first cyclosporine product delivered with nanomicellar (NCELL) technology. The NCELL formulation allows the drug molecule to overcome solubility difficulties, penetrating the eye’s aqueous layer where nanomicelles break up to release cyclosporine to penetrate ocular tissues.

The treatment was approved in 2018 based on results from 2 randomized studies that included over 1000 patients with dry eye disease. A recent placebo-controlled trial that included 744 patients found that a greater percentage of patients treated with Cequa had an increase of at least 10mm in Schirmer’s score (a measurement of tear production) from baseline compared with placebo (16.6% vs 9.2%, respectively; P<.01).

“Keratoconjunctivitis sicca causes symptoms of burning, stinging, itching, grittiness, and dryness, underscoring the need for tolerable drug therapy with a fast onset of action,” said Paul Karpecki, OD, FAAO, director of cornea services at the Kentucky Eye Institute in Lexington, KY.  “The Cequa clinical study results strengthen the rationale for using this product as a means to penetrate the tear film and improve drug delivery of cyclosporine into the eye.”

The most common adverse reactions associated with treatment included instillation site pain and conjunctival hyperemia.

Related Articles

Cequa is available as 0.9mg/mL strength preservative-free solution in 0.25mL single-use vials. Each box contains 6 pouches containing 10 vials each. The entire contents of each box should be dispensed intact. Solution from one individual single-use vial should be used immediately after opening for administration to one or both eyes; the remaining contents should be discarded immediately after administration.

For more information visit Cequa.com